ABCL — AbCellera Biologics
Median target
$13.5
calls from the last 12 months
Implied return
+6.0%
median target vs. price
Coverage
7 analysts · 11 calls
updated in the last 12 months
Consensus
7/0/0+7 net
Buy / Hold / Sell
Which analysts are behind ABCL's consensus?
See every current rating, price target and the analysts' track records for AbCellera Biologics — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 7 analysts with calls on ABCL updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
ABCL elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-08-24 | Insiders | Hayden Michael RDirector | Insider purchase | 53.6K sh @ $10.64 | $570K |
| 2026-08-18 | Insiders | Montalbano John S.Director | Insider purchase | 10.0K sh @ $11.03 | $110K |
| 2026-08-14 | Insiders | Booth AndrewChief Financial Officer | Insider purchase | 37.2K sh @ $10.32 | $384K |
| 2026-08-12 | Insiders | Hayden Michael RDirector | Insider purchase | 46.4K sh @ $10.37 | $481K |
More: insider activity · executive branch · trending